Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
BioAge Labs
Podcast
BioAge CEO talks NLRP3 and ‘pipeline in a pill’ ambitions
BioAge CEO Kristen Fortney sits down with Fierce Editor-in-Chief Ayla Ellison to discuss aging biology, inflammation and NLRP3 drugs.
Ayla Ellison
May 22, 2026 10:00am
BioAge CEO's big plans for 'multi-disease impact' of NLRP3 drug
May 14, 2026 11:00am
BioAge inks option agreement for Chinese biotech's obesity asset
Jun 3, 2025 2:06pm
BioAge axes obesity asset over liver toxicity
Jan 28, 2025 10:11am
BioAge secures Novartis deal worth up to $550M biobucks
Dec 18, 2024 10:44am
BioAge obesity study derailed by side effects 2 months after IPO
Dec 9, 2024 4:36am
